Doseology Sciences Inc. announced the successful soft launch of seven new adaptogenic mushroom products in the United States, and the upcoming launch of the product line in the Canadian market during the first quarter of 2022. Doseology's new medicinal mushroom products have successfully completed test marketing with overwhelmingly positive ratings and reviews. Being among the most comprehensive available on the market, they will help fill the growing demand for high-quality adaptogenic nutraceuticals.

The new line employs adaptogenic blends to improve on the single-extract tinctures commonly available. Blends have a higher market value because of increased user benefits and development challenges. Doseology has completed its application with Health Canada to become a "Licensed Dealer" under the Controlled Drugs and Substances Act (Canada), which would permit the production of psychedelic compounds including psilocybin and psilocin, and mark a significant milestone in achieving the Company's vision.